Estrella Immunopharma

Emeryville, United States

Estrella Immunopharma develops transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives.

$8.0M raised

Jan 2026

Post-IPO Equity

Biotechnology

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Estrella Immunopharma

How much funding has Estrella Immunopharma raised?

Estrella Immunopharma has raised $8.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.

Where is Estrella Immunopharma headquartered?

Estrella Immunopharma is headquartered in Emeryville, United States.

What does Estrella Immunopharma do?

Estrella Immunopharma develops transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives.

What stage is Estrella Immunopharma at?

Estrella Immunopharma is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 5, 2026.

MLA

"Estrella Immunopharma — Funding & Investors." VCBacked, January 5, 2026, https://www.vcbacked.co/company/estrella-immunopharma. Accessed July 2, 2026.

APA

VCBacked. (2026). Estrella Immunopharma — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/estrella-immunopharma

Wikipedia (cite web)

{{cite web |title=Estrella Immunopharma — Funding & Investors |url=https://www.vcbacked.co/company/estrella-immunopharma |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 5, 2026.